[DISCLOSURE]
Celltrion (068270) announced on Sept. 28 that it has signed a 151.4 billion won (US$136.42 million) contract with its affiliate
Celltrion Healthcare (091990) to supply biosimilar antibodies Truxima and Herzuma.
This amounts to 15.95 percent of its 2017 revenue and the contract is valid until Sept. 30.
By Hwang You-mee (
glamazon@heraldcorp.com)